Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rTAT-PTD-Trp2Δ is an experimental **cell-penetrating peptide (CPP) conjugate** designed to deliver the Trp2Δ peptide sequence into cells. The rTAT component serves as a potent cell-penetrating peptide, increasing membrane permeability to enable intracellular delivery. The drug is typically researched for its utility in facilitating intracellular delivery of biologically active peptide sequences, especially for modulating immune responses or intracellular protein-protein interactions. The precise mechanism of action depends on the cargo peptide (here Trp2Δ), but generally, the rTAT-PTD enables cytosolic transport, potentially for antitumor immunomodulation or related peptide therapeutics. There is no evidence of commercial availability or advanced clinical development for this specific conjugate[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rTAT-PTD-Trp2Δ.